Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Fineline Cube Mar 2, 2026
Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Fineline Cube Mar 2, 2026
Company Deals

Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine

Fineline Cube Nov 19, 2025

Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum...

Policy / Regulatory

NMPA Releases 98th RLD Catalog for Chemical Generics, Adding 48 New Specifications

Fineline Cube Nov 19, 2025

China’s National Medical Products Administration (NMPA) released the ninety-eighth batch of the Reference Listed Drugs...

Company Drug

Roche’s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma

Fineline Cube Nov 19, 2025

Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has granted...

Company Drug

Roche’s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial

Fineline Cube Nov 19, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced its investigational oral SERD giredestrant met the primary endpoint...

Company Drug

Hengrui’s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial

Fineline Cube Nov 18, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS‑6209 capsules, a novel...

Company Deals

Gate Bioscience Closes $65M Series B to Advance Molecular Gates to Clinic

Fineline Cube Nov 18, 2025

Gate Bioscience announced the close of its oversubscribed USD 65 million Series B financing led by...

Company Drug

Hengrui’s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b/2 Solid Tumor Trials

Fineline Cube Nov 18, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS‑4642, a home‑developed KRAS...

Company

Takeda Launches TCIC Digital Healthcare Innovation Center in Chengdu, a China‑First

Fineline Cube Nov 18, 2025

Takeda China, a subsidiary of Takeda Pharmaceutical Co. (TYO: 4502, NYSE: TAK), announced the official...

Company Drug

BeOne’s Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial

Fineline Cube Nov 18, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced its HER2‑targeted bispecific antibody zanidatamab (Ziihera)...

Company Drug

Biokin’s iza-bren ADC Achieves Dual PFS & OS Endpoints in Phase 3 Esophageal Cancer, a Global First

Fineline Cube Nov 18, 2025

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced its antibody-drug conjugate iza-bren (izalontamab brengitecan, BL‑B01D1)...

Company Deals

Resight Therapeutics Secures Tens‑Millions RMB Angel Round to Accelerate iPSC‑Derived Corneal Endothelial Cell Therapy

Fineline Cube Nov 18, 2025

Resight Therapeutics, a China‑based cell‑therapy pioneer founded in September 2024, announced the close of an Angel‑stage...

Company Drug

BMS and J&J Halt Phase III Milvexian Anticoagulant Trial for Acute Coronary Syndrome Patients

Fineline Cube Nov 18, 2025

Bristol‑Myers Squibb (BMS, NYSE: BMY) and Johnson & Johnson (J&J, NYSE: JNJ) announced the premature...

Company Drug

Jiangsu Hengrui Secures NMPA Approval for Tegileridine in Mechanically Ventilated ICU Patients

Fineline Cube Nov 18, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its μ‑opioid receptor (MOR)‑biased...

Company Deals

Johnson & Johnson to Acquire Halda Therapeutics for $3.05 B – Deal Highlights First‑in‑Class Oral RIPTAC HLD‑0915

Fineline Cube Nov 18, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced a definitive agreement to acquire Halda Therapeutics in an all‑cash...

Company Drug

Lundbeck’s Vyepti Secures Chinese NDA, Expands Asian Footprint

Fineline Cube Nov 17, 2025

Lundbeck A/S (OTCMKTS: HLUBF) announced that the Center for Drug Evaluation (CDE) of China’s National...

Company Deals

Suzhou Zelgen Biopharma to Deregister U.S. Subsidiary Gensun to Sharpen R&D Focus

Fineline Cube Nov 17, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced plans to de‑register and cancel its U.S. subsidiary,...

Company Drug

Akeso Secures NMPA Approval for AK152 – First Bispecific Antibody Targeting Alzheimer’s in China

Fineline Cube Nov 17, 2025

Akeso Inc. (HKG: 9926) announced that its self‑developed bispecific antibody AK152 has received regulatory approval...

Company Deals

MSD Acquires Cidara Therapeutics in $9.2‑Billion Deal to Expand Antiviral Portfolio

Fineline Cube Nov 17, 2025

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) disclosed a definitive acquisition agreement with Cidara Therapeutics, Inc....

Company Drug

Abbisko Therapeutics Reports Durable Response in Phase 3 MANEUVER Study for Pimicotinib (ABSK021) in TGCT

Fineline Cube Nov 17, 2025

Abbisko Therapeutics Co., Ltd. (HKG: 2256) released long‑term efficacy, safety and patient‑reported outcome data from its...

Company Drug

Zhejiang Jianfeng Group Secures NMPA Approval for JFAN‑1001/ Vinorelbine Combination in Advanced NSCLC

Fineline Cube Nov 17, 2025

Zhejiang Jianfeng Group Co., Ltd. (SHA: 600668) announced that its subsidiary Jianfeng Yien Biotechnology has obtained...

Posts pagination

1 … 40 41 42 … 628

Recent updates

  • Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy
  • HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline
  • Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug
  • GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC
  • InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Company Drug

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.